July 2019
Volume 60, Issue 9
ARVO Annual Meeting Abstract  |   July 2019
Gene therapy trials for hereditary retinal degenerations
Author Affiliations & Notes
  • Jacque L Duncan
    Ophthalmology, Univ of California - SF, San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Jacque Duncan, AGTC (C), Allergan, Inc. (F), Editas Medicine, Inc. (C), Neurotech USA, Inc. (F), Nightstar Limited (F), ProQR Therapeutics, Inc. (C), Second Sight Medical Products (F), SparingVIsion (C), Spark Therpeutics, Inc. (C)
  • Footnotes
    Support  Foundation Fighting Blindness
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 992. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jacque L Duncan; Gene therapy trials for hereditary retinal degenerations. Invest. Ophthalmol. Vis. Sci. 2019;60(9):992.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : With the advent of the first FDA approved gene therapy for eye disease in patients with RPE65-related retinal degeneration, there is increased interest by industry and patients in gene-based therapeutic clinical trials. What are the most promising approaches, and what are the most challenging aspects of gene based therapies? The presentation will provide an overview and update of gene therapy trials for patients with inherited retinal degenerations.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.